Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has analysts on the Bullish side this week.

October 2, 2018 - By Clifton Ray

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) LogoInvestors sentiment increased to 1.19 in 2018 Q2. Its up 0.14, from 1.05 in 2018Q1. It is positive, as 43 investors sold Regeneron Pharmaceuticals, Inc. shares while 157 reduced holdings. 67 funds opened positions while 171 raised stakes. 70.25 million shares or 1.33% more from 69.33 million shares in 2018Q1 were reported.
Jane Street Gp Ltd Liability Corp owns 23,974 shares. Proshare Advsr Ltd Limited Liability Company holds 0.25% or 109,766 shares. 3,000 are owned by Icon Advisers. Twin Tree Management L P has 23,082 shares. Global X Mngmt Com Ltd Liability Com stated it has 3,572 shares or 0.02% of all its holdings. Strs Ohio holds 0.07% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 47,200 shares. 4,590 are held by Sg Americas Securities Ltd Company. Century owns 912,128 shares or 0.32% of their US portfolio. Public Sector Pension Investment Board owns 4,382 shares or 0.01% of their US portfolio. Gulf Bank & Trust (Uk) reported 0.11% stake. Boston Common Asset Limited Liability holds 11,499 shares. Moreover, Finance Architects has 0.02% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Meeder Asset Mgmt reported 0% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). 970,817 were reported by Geode Capital Ltd. Westpac Banking Corporation holds 5,056 shares.

Since May 9, 2018, it had 0 insider purchases, and 8 insider sales for $143.17 million activity. $24.50 million worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares were sold by VAGELOS P ROY. $5.72M worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares were sold by SING GEORGE L. The insider Sanofi sold 121,601 shares worth $37.61M. GOLDSTEIN JOSEPH L had sold 4,000 shares worth $1.46M on Thursday, July 5. $3.37 million worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was sold by STAHL NEIL on Wednesday, May 23.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Ratings Coverage

Among 11 analysts covering Regeneron Pharmaceuticals (NASDAQ:REGN), 3 have Buy rating, 1 Sell and 7 Hold. Therefore 27% are positive. Regeneron Pharmaceuticals had 15 analyst reports since April 9, 2018 according to SRatingsIntel. Robert W. Baird downgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Friday, August 3 to “Neutral” rating. Canaccord Genuity maintained the stock with “Hold” rating in Friday, August 3 report. Argus Research maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Monday, July 16 with “Buy” rating. On Wednesday, June 27 the stock rating was upgraded by Oppenheimer to “Buy”. The company was maintained on Friday, August 3 by Morgan Stanley. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Equal-Weight” rating by Morgan Stanley on Friday, May 4. Morgan Stanley maintained it with “Equal-Weight” rating and $396 target in Friday, July 13 report. The firm has “Hold” rating by Oppenheimer given on Tuesday, May 1. The stock has “Market Perform” rating by Raymond James on Monday, April 9. The stock has “Neutral” rating by Guggenheim on Tuesday, May 1. Below is a list of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) latest ratings and price target changes.

01/10/2018 Broker: Cantor Fitzgerald Rating: Neutral New Target: $415 Initiates Coverage On
06/08/2018 Broker: Barclays Capital Old Rating: Underweight New Rating: Underweight Old Target: $290 New Target: $305 Maintain
03/08/2018 Broker: Canaccord Genuity Old Rating: Hold New Rating: Hold Old Target: $304 New Target: $390 Maintain
03/08/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $396 New Target: $409 Maintain
03/08/2018 Broker: Robert W. Baird Old Rating: Outperform New Rating: Neutral Downgrade
16/07/2018 Broker: Argus Research Old Rating: Buy New Rating: Buy Old Target: $383 New Target: $415 Maintain
13/07/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $370 New Target: $396 Maintain
27/06/2018 Broker: Oppenheimer Rating: Buy Upgrade
23/05/2018 Broker: Barclays Capital Rating: Sell New Target: $290.0000 Maintain
04/05/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $400 New Target: $370 Maintain

The stock increased 1.80% or $7.09 during the last trading session, reaching $401.32. About 498,738 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has declined 12.51% since October 2, 2017 and is downtrending. It has underperformed by 28.13% the S&P500.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, makes, and commercializes medicines for the treatment of serious medical conditions worldwide. The company has market cap of $43.32 billion. The Company’s products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It has a 29.14 P/E ratio. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer.

More notable recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news were published by: which released: “FDA to review sBLA for Praluent Injection as potential treatment to reduce MACE” on September 12, 2018, also with their article: “My Favorite Large-Cap Biotech Stock to Buy Now” published on September 26, 2018, published: “Premarket analyst action – healthcare” on October 01, 2018. More interesting news about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: and their article: “FDA Approves Regeneron’s (REGN) Treatment for Advanced Skin Cancer, FDA Approves Libtayo – Bloomberg” published on September 28, 2018 as well as‘s news article titled: “Regeneron and Sanofi’s Dupixent shows treatment benefit in adolescents with atopic dermatitis” with publication date: September 15, 2018.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.